Wall Street brokerages predict that NxStage Medical, Inc. (NASDAQ:NXTM) will post ($0.02) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for NxStage Medical’s earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at $0.02. NxStage Medical reported earnings of ($0.14) per share in the same quarter last year, which would indicate a positive year over year growth rate of 85.7%. The company is expected to announce its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that NxStage Medical will report full year earnings of ($0.02) per share for the current financial year, with EPS estimates ranging from ($0.15) to $0.13. For the next year, analysts expect that the company will report earnings of $0.09 per share, with EPS estimates ranging from ($0.05) to $0.25. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for NxStage Medical.
NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings results on Tuesday, August 7th. The medical device company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The company had revenue of $106.97 million for the quarter, compared to analysts’ expectations of $105.35 million. NxStage Medical had a negative net margin of 3.67% and a negative return on equity of 7.02%.
A number of analysts recently commented on the stock. BidaskClub cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Friday, July 20th. Zacks Investment Research cut shares of NxStage Medical from a “hold” rating to a “sell” rating in a research note on Saturday, August 11th. Finally, ValuEngine cut shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th.
Hedge funds and other institutional investors have recently bought and sold shares of the business. NumerixS Investment Technologies Inc purchased a new stake in NxStage Medical in the 2nd quarter worth approximately $122,000. Steward Partners Investment Advisory LLC lifted its stake in NxStage Medical by 714.3% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,700 shares of the medical device company’s stock worth $159,000 after purchasing an additional 5,000 shares in the last quarter. Keybank National Association OH purchased a new stake in NxStage Medical in the 2nd quarter worth approximately $212,000. Quantitative Systematic Strategies LLC purchased a new stake in NxStage Medical in the 2nd quarter worth approximately $216,000. Finally, Janus Henderson Group PLC purchased a new stake in NxStage Medical in the 2nd quarter worth approximately $234,000. Institutional investors and hedge funds own 83.15% of the company’s stock.
Shares of NXTM stock opened at $28.41 on Friday. NxStage Medical has a 12 month low of $22.70 and a 12 month high of $28.80.
About NxStage Medical
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Read More: Ex-Dividend
Get a free copy of the Zacks research report on NxStage Medical (NXTM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.